Sumatriptan
Product Images NDC 50436-0147

3 FDA label images from Unit Dose Services · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 50436-0147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl504360147)

Label Image (Lbl504360147)
Drug facts panel for Sumatriptan 50 mg tablets, labeled for Unit Dose Services with NDC 50436-0147. The panel states it contains 9 unit-dose tablets, each with 25 mg of sumatriptan succinate equivalent to 25 mg sumatriptan, and includes usage instructions and storage conditions. It lists packaging and manufacturing details with multiple lot and expiration date placeholders.*
FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
Line graph depicting the estimated probability of response over time in minutes from the initial dose for Sumatriptan at 25 mg, 50 mg, and 100 mg doses compared to placebo. The graph shows response probability increasing over 240 minutes for all doses, with higher doses generally showing greater response than placebo.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
A line graph showing the estimated probability of headache remission or relief over time in hours from the initial dose. The graph compares placebo with three dosages — 25 mg, 50 mg, and 100 mg — illustrating their effects within a 24-hour period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.